| Quinnipiac Medical Of Branford, Llc | |
|
960 Main St Branford CT 06405-3730 | |
| (203) 488-6358 | |
| (203) 481-5327 |
| Full Name | Quinnipiac Medical Of Branford, Llc |
|---|---|
| Speciality | Internal Medicine |
| Location | 960 Main St, Branford, Connecticut |
| Authorized Official Name and Position | Mary Kay Taylor (OFFICE MANAGER) |
| Authorized Official Contact | 2034886358 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Quinnipiac Medical Of Branford, Llc 960 Main St Branford CT 06405-3730 Ph: (203) 488-6358 | Quinnipiac Medical Of Branford, Llc 960 Main St Branford CT 06405-3730 Ph: (203) 488-6358 |
| NPI Number | 1982668240 |
|---|---|
| Provider Enumeration Date | 04/13/2006 |
| Last Update Date | 02/03/2022 |
| Medicare PECOS PAC ID | 8224920798 |
|---|---|
| Medicare Enrollment ID | O20040329000728 |
News Archive
Greatbatch, Inc., today announced results for its fourth quarter and full-year ended January 3, 2014 highlighted by 5% constant currency organic revenue growth for the full year 2013; 12% year over year improvement in adjusted operating income; and 19% improvement in adjusted diluted EPS over 2012.
Catholic Health Initiatives' (CHI) Institute for Research and Innovation's Center for Translational Research and BioFortis, Inc. have announced a joint strategic partnership to focus on CHI's vision in personalized healthcare initiatives for community hospitals across their system.
A multidisciplinary team from The University of Texas Medical Branch at Galveston has uncovered a Zika virus mutation that may be responsible for the explosive viral transmission in 2015/2016 and for the cause of microcephaly (babies with small heads) born to infected pregnant women.
Vanda Pharmaceuticals Inc. announced today that the U.S. Patent and Trademark Office has issued a notice of allowance for its patent application of a microsphere, long-acting injectable formulation of its antipsychotic product, Fanapt™ (iloperidone). When issued, this U.S. patent will expire on October 30, 2022, and in addition, the U.S. Patent and Trademark Office has granted a patent term adjustment of 300 days, leading to an effective expiration date of August 26, 2023.
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982668240 | NPI | - | NPPES |
| C02646 | Other | CT | MEDICARE |
| 50QUINLLCT01 | Other | CT | ANTHEM BCBS |
| CH3185 | Other | CT | RAILROAD MEDICARE |
| 004208931 | Medicaid | CT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | (* (Not Available)) | Primary |
| Provider Name | Karen A Stemler |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1134164650 PECOS PAC ID: 5991604621 Enrollment ID: I20040102000038 |
News Archive
Greatbatch, Inc., today announced results for its fourth quarter and full-year ended January 3, 2014 highlighted by 5% constant currency organic revenue growth for the full year 2013; 12% year over year improvement in adjusted operating income; and 19% improvement in adjusted diluted EPS over 2012.
Catholic Health Initiatives' (CHI) Institute for Research and Innovation's Center for Translational Research and BioFortis, Inc. have announced a joint strategic partnership to focus on CHI's vision in personalized healthcare initiatives for community hospitals across their system.
A multidisciplinary team from The University of Texas Medical Branch at Galveston has uncovered a Zika virus mutation that may be responsible for the explosive viral transmission in 2015/2016 and for the cause of microcephaly (babies with small heads) born to infected pregnant women.
Vanda Pharmaceuticals Inc. announced today that the U.S. Patent and Trademark Office has issued a notice of allowance for its patent application of a microsphere, long-acting injectable formulation of its antipsychotic product, Fanapt™ (iloperidone). When issued, this U.S. patent will expire on October 30, 2022, and in addition, the U.S. Patent and Trademark Office has granted a patent term adjustment of 300 days, leading to an effective expiration date of August 26, 2023.
› Verified 1 days ago
| Provider Name | Andrea Radebold |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1942264288 PECOS PAC ID: 2365421385 Enrollment ID: I20040714001109 |
News Archive
Greatbatch, Inc., today announced results for its fourth quarter and full-year ended January 3, 2014 highlighted by 5% constant currency organic revenue growth for the full year 2013; 12% year over year improvement in adjusted operating income; and 19% improvement in adjusted diluted EPS over 2012.
Catholic Health Initiatives' (CHI) Institute for Research and Innovation's Center for Translational Research and BioFortis, Inc. have announced a joint strategic partnership to focus on CHI's vision in personalized healthcare initiatives for community hospitals across their system.
A multidisciplinary team from The University of Texas Medical Branch at Galveston has uncovered a Zika virus mutation that may be responsible for the explosive viral transmission in 2015/2016 and for the cause of microcephaly (babies with small heads) born to infected pregnant women.
Vanda Pharmaceuticals Inc. announced today that the U.S. Patent and Trademark Office has issued a notice of allowance for its patent application of a microsphere, long-acting injectable formulation of its antipsychotic product, Fanapt™ (iloperidone). When issued, this U.S. patent will expire on October 30, 2022, and in addition, the U.S. Patent and Trademark Office has granted a patent term adjustment of 300 days, leading to an effective expiration date of August 26, 2023.
› Verified 1 days ago
| Provider Name | Joseph L Quaranta |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1902860232 PECOS PAC ID: 9830233501 Enrollment ID: I20100218000432 |
News Archive
Greatbatch, Inc., today announced results for its fourth quarter and full-year ended January 3, 2014 highlighted by 5% constant currency organic revenue growth for the full year 2013; 12% year over year improvement in adjusted operating income; and 19% improvement in adjusted diluted EPS over 2012.
Catholic Health Initiatives' (CHI) Institute for Research and Innovation's Center for Translational Research and BioFortis, Inc. have announced a joint strategic partnership to focus on CHI's vision in personalized healthcare initiatives for community hospitals across their system.
A multidisciplinary team from The University of Texas Medical Branch at Galveston has uncovered a Zika virus mutation that may be responsible for the explosive viral transmission in 2015/2016 and for the cause of microcephaly (babies with small heads) born to infected pregnant women.
Vanda Pharmaceuticals Inc. announced today that the U.S. Patent and Trademark Office has issued a notice of allowance for its patent application of a microsphere, long-acting injectable formulation of its antipsychotic product, Fanapt™ (iloperidone). When issued, this U.S. patent will expire on October 30, 2022, and in addition, the U.S. Patent and Trademark Office has granted a patent term adjustment of 300 days, leading to an effective expiration date of August 26, 2023.
› Verified 1 days ago
| Provider Name | Richard E Kaufman |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1215991575 PECOS PAC ID: 9739071218 Enrollment ID: I20100305000458 |
News Archive
Greatbatch, Inc., today announced results for its fourth quarter and full-year ended January 3, 2014 highlighted by 5% constant currency organic revenue growth for the full year 2013; 12% year over year improvement in adjusted operating income; and 19% improvement in adjusted diluted EPS over 2012.
Catholic Health Initiatives' (CHI) Institute for Research and Innovation's Center for Translational Research and BioFortis, Inc. have announced a joint strategic partnership to focus on CHI's vision in personalized healthcare initiatives for community hospitals across their system.
A multidisciplinary team from The University of Texas Medical Branch at Galveston has uncovered a Zika virus mutation that may be responsible for the explosive viral transmission in 2015/2016 and for the cause of microcephaly (babies with small heads) born to infected pregnant women.
Vanda Pharmaceuticals Inc. announced today that the U.S. Patent and Trademark Office has issued a notice of allowance for its patent application of a microsphere, long-acting injectable formulation of its antipsychotic product, Fanapt™ (iloperidone). When issued, this U.S. patent will expire on October 30, 2022, and in addition, the U.S. Patent and Trademark Office has granted a patent term adjustment of 300 days, leading to an effective expiration date of August 26, 2023.
› Verified 1 days ago
| Provider Name | Jill M Mceachern |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1053392837 PECOS PAC ID: 4880658863 Enrollment ID: I20120426000499 |
News Archive
Greatbatch, Inc., today announced results for its fourth quarter and full-year ended January 3, 2014 highlighted by 5% constant currency organic revenue growth for the full year 2013; 12% year over year improvement in adjusted operating income; and 19% improvement in adjusted diluted EPS over 2012.
Catholic Health Initiatives' (CHI) Institute for Research and Innovation's Center for Translational Research and BioFortis, Inc. have announced a joint strategic partnership to focus on CHI's vision in personalized healthcare initiatives for community hospitals across their system.
A multidisciplinary team from The University of Texas Medical Branch at Galveston has uncovered a Zika virus mutation that may be responsible for the explosive viral transmission in 2015/2016 and for the cause of microcephaly (babies with small heads) born to infected pregnant women.
Vanda Pharmaceuticals Inc. announced today that the U.S. Patent and Trademark Office has issued a notice of allowance for its patent application of a microsphere, long-acting injectable formulation of its antipsychotic product, Fanapt™ (iloperidone). When issued, this U.S. patent will expire on October 30, 2022, and in addition, the U.S. Patent and Trademark Office has granted a patent term adjustment of 300 days, leading to an effective expiration date of August 26, 2023.
› Verified 1 days ago
| Provider Name | Thomas D'addario |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1760877989 PECOS PAC ID: 9234441643 Enrollment ID: I20180717000628 |
News Archive
Greatbatch, Inc., today announced results for its fourth quarter and full-year ended January 3, 2014 highlighted by 5% constant currency organic revenue growth for the full year 2013; 12% year over year improvement in adjusted operating income; and 19% improvement in adjusted diluted EPS over 2012.
Catholic Health Initiatives' (CHI) Institute for Research and Innovation's Center for Translational Research and BioFortis, Inc. have announced a joint strategic partnership to focus on CHI's vision in personalized healthcare initiatives for community hospitals across their system.
A multidisciplinary team from The University of Texas Medical Branch at Galveston has uncovered a Zika virus mutation that may be responsible for the explosive viral transmission in 2015/2016 and for the cause of microcephaly (babies with small heads) born to infected pregnant women.
Vanda Pharmaceuticals Inc. announced today that the U.S. Patent and Trademark Office has issued a notice of allowance for its patent application of a microsphere, long-acting injectable formulation of its antipsychotic product, Fanapt™ (iloperidone). When issued, this U.S. patent will expire on October 30, 2022, and in addition, the U.S. Patent and Trademark Office has granted a patent term adjustment of 300 days, leading to an effective expiration date of August 26, 2023.
› Verified 1 days ago
| Provider Name | Alyse Marie Como |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1538935663 PECOS PAC ID: 7618327149 Enrollment ID: I20231227000254 |
News Archive
Greatbatch, Inc., today announced results for its fourth quarter and full-year ended January 3, 2014 highlighted by 5% constant currency organic revenue growth for the full year 2013; 12% year over year improvement in adjusted operating income; and 19% improvement in adjusted diluted EPS over 2012.
Catholic Health Initiatives' (CHI) Institute for Research and Innovation's Center for Translational Research and BioFortis, Inc. have announced a joint strategic partnership to focus on CHI's vision in personalized healthcare initiatives for community hospitals across their system.
A multidisciplinary team from The University of Texas Medical Branch at Galveston has uncovered a Zika virus mutation that may be responsible for the explosive viral transmission in 2015/2016 and for the cause of microcephaly (babies with small heads) born to infected pregnant women.
Vanda Pharmaceuticals Inc. announced today that the U.S. Patent and Trademark Office has issued a notice of allowance for its patent application of a microsphere, long-acting injectable formulation of its antipsychotic product, Fanapt™ (iloperidone). When issued, this U.S. patent will expire on October 30, 2022, and in addition, the U.S. Patent and Trademark Office has granted a patent term adjustment of 300 days, leading to an effective expiration date of August 26, 2023.
› Verified 1 days ago
News Archive
Greatbatch, Inc., today announced results for its fourth quarter and full-year ended January 3, 2014 highlighted by 5% constant currency organic revenue growth for the full year 2013; 12% year over year improvement in adjusted operating income; and 19% improvement in adjusted diluted EPS over 2012.
Catholic Health Initiatives' (CHI) Institute for Research and Innovation's Center for Translational Research and BioFortis, Inc. have announced a joint strategic partnership to focus on CHI's vision in personalized healthcare initiatives for community hospitals across their system.
A multidisciplinary team from The University of Texas Medical Branch at Galveston has uncovered a Zika virus mutation that may be responsible for the explosive viral transmission in 2015/2016 and for the cause of microcephaly (babies with small heads) born to infected pregnant women.
Vanda Pharmaceuticals Inc. announced today that the U.S. Patent and Trademark Office has issued a notice of allowance for its patent application of a microsphere, long-acting injectable formulation of its antipsychotic product, Fanapt™ (iloperidone). When issued, this U.S. patent will expire on October 30, 2022, and in addition, the U.S. Patent and Trademark Office has granted a patent term adjustment of 300 days, leading to an effective expiration date of August 26, 2023.
› Verified 1 days ago
Center For Orthopaedics Division Of Connecticut Orthopaedic Specialist Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1224 Main St, Branford, CT 06405 Phone: 203-752-3100 Fax: 203-752-9291 | |
Fair Haven Community Health Clinic Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 221 W Main St, Branford, CT 06405 Phone: 203-777-7411 Fax: 203-777-8506 | |
Livella Care, Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 4 Brushy Plain Rd, Suite 519, Branford, CT 06405 Phone: 203-214-4527 | |
Branford Internal Medicine Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 500 E Main St, Suite 212, Branford, CT 06405 Phone: 203-481-5665 Fax: 203-481-5524 | |
J.t. Bristol, M.d., Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 84 N Main St, Branford, CT 06405 Phone: 203-483-2015 Fax: 203-483-2016 | |
Digestive Disease Associates, Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1224 Main St, Branford, CT 06405 Phone: 203-481-0315 Fax: 203-481-6788 | |
American Natural Health Care And Medicine, Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 365 E Main St, Suite 4, Branford, CT 06405 Phone: 203-589-9349 Fax: 888-729-5733 |